Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going through clinical trials. Now he’s raised some $615 million from top investors to buy stalled drugs and use AI to stress test them …
A physician examines whether the FDA’s loosening of wellness peptide restrictions means these compounds are actually safe and proven. The answer may surprise you.
Trump promises maximum consumer choice in health care. Yet, he is making it harder to access home -based care favored by older adults and young people with disabilities.
Clinical genome sequencing now delivers genetic diagnoses for about 1 in 4 suspected rare disease patients, guiding targeted care and shaping newborn screening worldwide.
Len is a gamechanging drug to prevent HIV infections, priced by Gilead at $28,200. Limited drug is available at cost to low-income countries. Research ethics are discussed.
Quarterly RNA drug plozasiran turns off a liver gene, sharply lowering life‑threatening pancreatitis attacks in a rare genetic disorder.
In this week’s edition of InnovationRx, we look at the top self-made healthcare entrepreneurs, the latest 30 Under 30 Science & Healthcare list, and more.
Racism was once pushed underground in clinical settings. Have we made progress?
UnitedHealth Group earnings next week may signal whether health insurance companies are getting a handle on rising costs dragging down the industry.
Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.